Saptalis Pharmaceuticals has announced the commercial launch of Cyclosporine Ophthalmic Emulsion 0.05 percent, available in 30- and 60-count single-use vials, reinforcing its commitment to expanding access to high-quality treatments.

Dry eye disease affects millions of patients worldwide. Cyclosporine Ophthalmic Emulsion 0.05 percent is a preservative-free, single-use formulation indicated to increase tear production and provides a convenient option for managing inflammation-associated tear deficiency.

In addition to Cyclosporine Ophthalmic Emulsion, Saptalis also announced the approval and launch of several other products across multiple therapeutic categories:

• Tofacitinib Oral Solution, 1 mg/mL (240 mL): Indicated for the treatment of autoimmune and inflammatory conditions, including rheumatoid arthritis and related disorders.
• Hydroxyzine HCl Oral Solution, USP 10 mg/5 mL (473 mL): Indicated for the symptomatic relief of anxiety and tension, and for the management of pruritus due to allergic conditions.
• Chlorpromazine HCl Oral Concentrate, 30 mg/mL (120 mL) and 100 mg/mL (240 mL): Indicated for the treatment of schizophrenia, psychotic disorders, and for the control of severe nausea and vomiting.
• Desoximetasone Cream, USP 0.05 percent and 0.25 percent (15 g and 60 g): Indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
• Fluocinonide Topical Solution, USP 0.05 percent (20 mL and 60 mL): Indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive scalp and skin conditions.

Polireddy Dondeti, President and CEO, Saptalis Pharmaceuticals, said, “With these launches, we continue to grow our generic business segment with US-based manufacturing, while maintaining our primary focus on advancing our pipeline of innovative branded therapies addressing unmet medical needs.”

These additions strengthen Saptalis’ portfolio of liquid and semi-solid dosage forms across ophthalmology, dermatology, psychiatry, and allergy-related therapeutic areas.